LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
Perspective Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $3.66
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS